دورية أكاديمية
أعرض في EDS

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.

التفاصيل البيبلوغرافية
العنوان: Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.
المؤلفون: Thomas SE; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands. sarah.thomas@radboudumc.nl., Barenbrug L; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands., Hannink G; Department of Medical Imaging, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands., Seyger MMB; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands., de Jong EMGJ; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.; Radboud University, Nijmegen, The Netherlands., van den Reek JMPA; Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.
المصدر: Drugs [Drugs] 2024 May; Vol. 84 (5), pp. 565-578. Date of Electronic Publication: 2024 Apr 17.
نوع المنشور: Journal Article; Systematic Review; Meta-Analysis
اللغة: English
بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 7600076 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1950 (Electronic) Linking ISSN: 00126667 NLM ISO Abbreviation: Drugs Subsets: MEDLINE
أسماء مطبوعة: Publication: Auckland : Adis, Springer International
Original Publication: New York, ADIS Press [etc.]
مواضيع طبية MeSH: Psoriasis*/drug therapy , Interleukin-17*/antagonists & inhibitors , Interleukin-23*/antagonists & inhibitors, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/adverse effects ; Dermatologic Agents/therapeutic use ; Dermatologic Agents/pharmacology ; Dermatologic Agents/adverse effects
مستخلص: Background and Objective: The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking. Therefore, our objective was to assess the drug survival of IL-17 and IL-23 inhibitors for psoriasis.
Methods: A search of PubMed, Embase, Cochrane Library and Web of Science was conducted (last search 27 December, 2023). Inclusion criteria were (1) cohort study; (2) patients aged ≥ 18 years with plaque psoriasis; and (3) evaluation of drug survival of at least one of the IL-17 and IL-23 inhibitors. Exclusion criteria were: primary focus on patients with psoriatic arthritis, fewer than ten study subjects and another language than English. The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed. Survival probabilities at monthly intervals were extracted from Kaplan-Meier curves using a semi-automated tool. Data were pooled using a non-parametric random-effects model to retrieve distribution-free summary survival curves. Summary drug survival curves were constructed per biologic for different discontinuation reasons: overall, ineffectiveness and adverse events, and split for the effect modifier biologic naivety. Results were analysed separately for registry/electronic health record data and for pharmacy/claims data.
Results: A total of 69 studies aggregating drug survival outcomes of 48,704 patients on secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, and tildrakizumab were included. Summary drug survival estimates of registry/electronic health record studies for overall, ineffectiveness and adverse event related drug survival were high (all point estimates ≥ 0.8 at year 1) for included biologics, with highest estimates for guselkumab and risankizumab. All estimates for drug survival were higher in biologic naive than in experienced patients. Estimates of pharmacy/claims databases were substantially lower than estimates from the primary analyses based on registry/electronic health record data.
Conclusions: This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies.
(© 2024. The Author(s).)
References: J Dermatolog Treat. 2019 Mar;30(2):150-151. (PMID: 29733240)
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1240-1247. (PMID: 31953892)
JAAD Int. 2021 Jul 08;4:49-51. (PMID: 34409392)
Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275)
J Dermatolog Treat. 2022 May;33(3):1749-1753. (PMID: 33430676)
J Dermatol. 2022 Jan;49(1):95-105. (PMID: 34747071)
Clin Cosmet Investig Dermatol. 2022 Oct 20;15:2245-2252. (PMID: 36304759)
Dermatol Ther (Heidelb). 2023 Mar;13(3):787-801. (PMID: 36723775)
J Am Acad Dermatol. 2019 Jul;81(1):270-272. (PMID: 30690047)
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e82-e84. (PMID: 30176180)
J Dtsch Dermatol Ges. 2024 Jan;22(1):34-42. (PMID: 37926830)
Stat Med. 2012 Dec 20;31(29):3805-20. (PMID: 22763950)
Australas J Dermatol. 2023 Nov;64(4):504-513. (PMID: 37705180)
Dermatol Ther (Heidelb). 2021 Dec;11(6):2207-2215. (PMID: 34561788)
J Dermatol. 2023 Jun;50(6):753-765. (PMID: 36786158)
Dermatol Ther (Heidelb). 2021 Dec;11(6):2107-2121. (PMID: 34661864)
J Dermatolog Treat. 2022 Jun;33(4):2352-2357. (PMID: 34315331)
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):568-575. (PMID: 38147467)
Int J Dermatol. 2020 May;59(5):633-639. (PMID: 32173862)
J Dermatolog Treat. 2020 Jun;31(4):342-343. (PMID: 30957586)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Expert Opin Biol Ther. 2023 Apr;23(4):371-381. (PMID: 36971507)
Dermatol Ther. 2021 Mar;34(2):e14798. (PMID: 33484067)
J Invest Dermatol. 2023 Nov;143(11):2211-2218.e4. (PMID: 37119965)
Acta Derm Venereol. 2022 Jan 18;102:adv00631. (PMID: 34904684)
Expert Opin Biol Ther. 2021 Feb;21(2):279-286. (PMID: 33170052)
Am J Clin Dermatol. 2022 Nov;23(6):891-904. (PMID: 35976568)
Actas Dermosifiliogr (Engl Ed). 2018 Oct;109(8):674-676. (PMID: 30041866)
Trials. 2007 Jun 07;8:16. (PMID: 17555582)
J Dermatolog Treat. 2023 Dec;34(1):2133531. (PMID: 36200762)
Dermatology. 2022;238(5):897-903. (PMID: 35263743)
Semin Arthritis Rheum. 2022 Apr;53:151979. (PMID: 35183936)
Dermatol Ther. 2021 Mar;34(2):e14808. (PMID: 33491259)
BMC Dermatol. 2018 Jul 11;18(1):5. (PMID: 29996929)
Trials. 2015 Nov 03;16:495. (PMID: 26530985)
Stat Med. 2007 Oct 30;26(24):4505-19. (PMID: 17348080)
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e716-e718. (PMID: 32343430)
Dermatol Ther (Heidelb). 2023 Jan;13(1):235-244. (PMID: 36436161)
Stat Med. 2002 Nov 30;21(22):3337-51. (PMID: 12407676)
Br J Dermatol. 2019 Sep;181(3):450-458. (PMID: 30729500)
Dermatol Ther (Heidelb). 2022 Apr;12(4):971-987. (PMID: 35305255)
J Dermatolog Treat. 2022 Feb;33(1):354-360. (PMID: 32319327)
J Dermatolog Treat. 2022 Sep;33(6):2827-2837. (PMID: 35635185)
Stat Med. 2014 Jul 10;33(15):2521-37. (PMID: 24532219)
J Am Acad Dermatol. 2020 Apr;82(4):927-935. (PMID: 31712178)
Br J Dermatol. 2019 Dec;181(6):1265-1271. (PMID: 30822358)
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1524-1528. (PMID: 31953883)
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. (PMID: 30772098)
Br J Dermatol. 2021 Sep;185(3):660-662. (PMID: 33913516)
Lancet. 2021 Apr 3;397(10281):1301-1315. (PMID: 33812489)
BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354)
Acta Derm Venereol. 2018 Jul 11;98(7):648-654. (PMID: 29405245)
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):689-697. (PMID: 36562663)
Dermatol Ther (Heidelb). 2024 Jan;14(1):99-114. (PMID: 38019410)
J Dermatol. 2023 Nov;50(11):1415-1426. (PMID: 37615243)
JAMA Dermatol. 2022 Oct 01;158(10):1131-1141. (PMID: 35791876)
J Dermatolog Treat. 2023 Dec;34(1):2229465. (PMID: 37403477)
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):698-710. (PMID: 36562700)
J Dermatol. 2020 Jan;47(1):33-40. (PMID: 31696543)
Dermatol Ther (Heidelb). 2023 Feb;13(2):465-476. (PMID: 36472791)
Sci Rep. 2018 Oct 30;8(1):16068. (PMID: 30375427)
Dermatol Ther. 2021 Sep;34(5):e15081. (PMID: 34339549)
Dermatol Ther. 2022 Jul;35(7):e15510. (PMID: 35419886)
J Clin Med. 2022 Aug 30;11(17):. (PMID: 36079026)
J Invest Dermatol. 2015 Jul;135(7):1-5. (PMID: 26066896)
Med J Malaysia. 2022 Nov;77(6):689-695. (PMID: 36448386)
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1568-1577. (PMID: 35569014)
J Am Acad Dermatol. 2019 Jul;81(1):273-275. (PMID: 30790602)
Expert Opin Biol Ther. 2023 Apr;23(4):365-370. (PMID: 36927246)
Dermatol Ther (Heidelb). 2023 Apr;13(4):1053-1068. (PMID: 36929120)
Australas J Dermatol. 2022 Aug;63(3):303-311. (PMID: 35809080)
Acta Derm Venereol. 2022 Aug 11;102:adv00755. (PMID: 35788690)
JAMA. 2000 Apr 19;283(15):2008-12. (PMID: 10789670)
J Dermatolog Treat. 2018 Aug;29(5):460-466. (PMID: 29076754)
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e626-e627. (PMID: 35305054)
Am J Clin Dermatol. 2021 Jul;22(4):567-579. (PMID: 33786754)
Ann Dermatol. 2022 Oct;34(5):321-330. (PMID: 36198623)
Clin Drug Investig. 2023 Jul;43(7):517-527. (PMID: 37402097)
Br J Dermatol. 2021 Jun;184(6):1094-1105. (PMID: 33289075)
Drugs R D. 2023 Jun;23(2):155-163. (PMID: 37155121)
Front Med (Lausanne). 2023 Jul 03;10:1196966. (PMID: 37469659)
Int J Dermatol. 2019 Jun;58(6):631-641. (PMID: 30973647)
Pharmaceutics. 2023 Nov 21;15(12):. (PMID: 38139989)
BMJ. 2021 Mar 29;372:n160. (PMID: 33781993)
Ann Intern Med. 2013 Feb 19;158(4):280-6. (PMID: 23420236)
Br J Dermatol. 2019 Jan;180(1):15-16. (PMID: 30604556)
Front Med (Lausanne). 2021 Mar 18;7:625755. (PMID: 33816514)
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. (PMID: 33349983)
Front Pharmacol. 2022 May 17;13:880985. (PMID: 35656306)
JAMA Dermatol. 2022 May 1;158(5):513-522. (PMID: 35319735)
Pharmacoepidemiol Drug Saf. 2020 Jun;29(6):675-683. (PMID: 32364664)
المشرفين على المادة: 0 (Interleukin-17)
0 (Interleukin-23)
0 (Antibodies, Monoclonal, Humanized)
BTY153760O (ixekizumab)
0 (Dermatologic Agents)
تواريخ الأحداث: Date Created: 20240417 Date Completed: 20240620 Latest Revision: 20240623
رمز التحديث: 20240623
مُعرف محوري في PubMed: PMC11190018
DOI: 10.1007/s40265-024-02028-1
PMID: 38630365
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-1950
DOI:10.1007/s40265-024-02028-1